VitaDX
Updated: January 04, 2026
Allan Rodriguez, CEO
Country: France | Funding: €4.7M (+)
Founded: 2014
Website: http://vitadx.com/en/
VitaDX is developing a non-invasive, AI-based test for the early detection of bladder cancer. It is based on VisioCyt technology, which uses deep learning and computer vision algorithms to analyze and diagnose digital cytology specimens. The test can be performed using a simple urine sample or screening data (for asymptomatic, high-risk patients). The company also offers the VisioCyt Thyroid test for diagnosing thyroid cancer using fine-needle aspiration biopsy.
Founded: 2014
Website: http://vitadx.com/en/
VitaDX is developing a non-invasive, AI-based test for the early detection of bladder cancer. It is based on VisioCyt technology, which uses deep learning and computer vision algorithms to analyze and diagnose digital cytology specimens. The test can be performed using a simple urine sample or screening data (for asymptomatic, high-risk patients). The company also offers the VisioCyt Thyroid test for diagnosing thyroid cancer using fine-needle aspiration biopsy.
